Shopping Cart
- Remove All
Your shopping cart is currently empty
HG-12-6 is a type II inhibitor of IRAK4, demonstrating preferential binding to unphosphorylated inactive IRAK4 (IC50: 165 nM) and modulating IRAK4 activity in autoimmunity and inflammation.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,720 | 3-6 months | |
| 50 mg | $3,580 | 3-6 months | |
| 100 mg | $4,900 | 3-6 months |
| Description | HG-12-6 is a type II inhibitor of IRAK4, demonstrating preferential binding to unphosphorylated inactive IRAK4 (IC50: 165 nM) and modulating IRAK4 activity in autoimmunity and inflammation. |
| Targets&IC50 | IRAK4:2876 nM , IRAK4:165 nM |
| In vitro | HG-12-6 has a better binding affinity for the unphosphorylated inactive IRAK4 kinase domain (IC50 of 165 nM) than the phosphorylated active IRAK4 kinase domain (IC50 of 2876 nM).The in-house compound HG-12-6 has a similar chemical scaffold as Ponatinib.?The most differentiating components are the head of the inhibitor and the lack of a methyl substituent on ring A. Without the methyl substituent on ring A, the entire HG-12-6 molecule shifts inward to the ATP pocket in comparison with the binding mode of Ponatinib. |
| Molecular Weight | 580.62 |
| Formula | C29H27F3N6O2S |
| Cas No. | 2222354-57-4 |
| Relative Density. | 1.444 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.